Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 21.
doi: 10.1038/s42255-025-01396-6. Online ahead of print.

Microbial metabolite indole-3-propionic acid drives mitochondrial respiration in CD4+ T cells to confer protection against intestinal inflammation

Affiliations

Microbial metabolite indole-3-propionic acid drives mitochondrial respiration in CD4+ T cells to confer protection against intestinal inflammation

Qing Li et al. Nat Metab. .

Abstract

The gut microbiota and its metabolites critically regulate immune cell phenotype, function and energy metabolism. We screened a collection of gut microbiota-related metabolites to identify modulators of mitochondrial metabolism in T cells. Here we show that indole-3-propionic acid (IPA) stimulates mitochondrial respiration of CD4+ T cells by increasing fatty acid oxidation (FAO) and amino acid oxidation (AAO), while inhibiting glycolytic capacity. IPA also impacts CD4+ T cell behaviour by inhibiting their differentiation to type 1 and type 17 helper T cell phenotypes. Mechanistically, the metabolic and immune effects of IPA are mediated by peroxisome proliferator-activated receptor-β/δ. The administration of IPA rescues mitochondria respiration in mice with gut bacteria depletion or colitis by enhancing FAO and AAO in colonic CD4+ T cells. Adoptive transfer experiments show that IPA acts on CD4+ T cells to exert its protective effect against inflammation. Collectively, our study reveals that the anti-inflammatory effects of IPA are mediated by metabolic reprogramming of CD4+ T cells toward the enhancement of mitochondrial respiration.

PubMed Disclaimer

Conflict of interest statement

Competing interests: H.S. reports lecture fees, board membership or consultancy from Carenity, AbbVie, Astellas, Danone, Ferring, Mayoly Spindler, MSD, Novartis, Roche, Tillots, Enterome, BiomX, Takeda and Biocodex, has stocks from Enterome, and is co-founder of Exeliom Biosciences. K.A. reports lecture fees, board membership or consultancy from AbbVie, Ferring, Johnson & Johnson, Takeda and Lilly. All other authors declare no competing interests.

References

    1. Glassner, K. L., Abraham, B. P. & Quigley, E. M. M. The microbiome and inflammatory bowel disease. J. Allergy Clin. Immunol. 145, 16–27 (2020). - PubMed - DOI
    1. Lee, M. & Chang, E. B. Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues. Gastroenterology 160, 524–537 (2021). - PubMed - DOI
    1. Hayward, J. A., Mathur, A., Ngo, C. & Man, S. M. Cytosolic recognition of microbes and pathogens: inflammasomes in action. Microbiol Mol. Biol. Rev. 82, e00015–e00018 (2018). - PubMed - PMC - DOI
    1. Krautkramer, K. A., Fan, J. & Backhed, F. Gut microbial metabolites as multi-kingdom intermediates. Nat. Rev. Microbiol. 19, 77–94 (2021). - PubMed - DOI
    1. Shi, N., Li, N., Duan, X. & Niu, H. Interaction between the gut microbiome and mucosal immune system. Mil. Med. Res. 4, 14 (2017). - PubMed - PMC

LinkOut - more resources